劉 興璟

Medicine & Life Sciences

1. ErbB Receptors 100%
2. Acute Myeloid Leukemia 97%
3. Lung Neoplasms 92%
4. Non-Small Cell Lung Carcinoma 84%
5. Myeloid Cells 74%
6. Mutation 59%
7. 2-dimethylamino-N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)acetamide 54%
8. Apoptosis 48%
9. Down-Regulation 42%
10. Thalassemia 41%
11. Tubulin Modulators 36%
12. Protein-Tyrosine Kinases 36%
13. human TERT protein 34%
14. Adenocarcinoma of Lung 32%
15. Arsenic Trioxide 30%
16. Alleles 30%
17. Uridine Diphosphate 29%
18. 5-phenyl-thiazol-2-ylamine 29%
19. Hemoglobins 28%
20. Cisplatin 24%
21. Drug Therapy 24%
22. Pandemics 24%
23. Platinum 24%
24. Survival 24%
25. Neoplasm Metastasis 24%
26. N-methylisoindigotin 23%
27. Neoplasms 23%
28. Paclitaxel 22%
29. Drug Resistance 22%
30. Point Mutation 22%
31. Genes 21%
32. Erlotinib Hydrochloride 20%
33. Human Influenza 20%
34. Progression-Free Survival 20%
35. Interferons 20%
36. Genotype 20%
37. Interleukin-10 20%
38. HL-60 Cells 19%
39. Therapeutics 18%
40. Population 18%
41. Tuberculosis 18%
42. Brain 18%
43. Hematopoietic Stem Cells 18%
44. Hepatocellular Carcinoma 18%
45. 2-Methoxyestradiol 17%
46. Hemagglutination 17%
47. Acetyltransferases 17%
48. T-Lymphocytes 16%
49. Smoking 16%